ATAI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AtaiBeckley Inc. (ATAI) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the recent price drop, the company's strong pipeline in next-generation psychiatry, significant insider and hedge fund buying, and positive trial results for its lead assets position it well for future growth. The technical indicators and options data suggest a neutral to slightly positive sentiment, and analysts have given the stock high price targets with buy ratings. The financial performance shows substantial revenue growth, indicating progress. This makes ATAI a compelling long-term investment opportunity.
The MACD is positive and contracting, suggesting a potential reversal or stabilization. RSI is neutral at 40.423, and moving averages are converging, indicating no strong trend. Key support is at $3.59, and resistance is at $4.277. The stock is near its support level, which could present a good entry point.
Hedge funds and insiders are significantly increasing their holdings.
Positive results from EMP-01 phase 2a trial for Social Anxiety Disorder.
Analysts have initiated coverage with buy ratings and high price targets ($11-$16).
Revenue growth of 1772.50% YoY in Q3 2025.
Recent price drop of 14.06% in the regular market and 10.37% in pre-market trading.
Net income remains negative, though improving.
In Q3 2025, revenue increased by 1772.50% YoY to $749,000. Net income improved by 132.34% YoY but remains negative at -$61.07M. EPS improved by 75% YoY to -0.28. Gross margin remains at 100%.
Analysts from Guggenheim and JonesResearch have initiated buy ratings with price targets of $11 and $16, citing the company's leadership in next-generation psychiatry and its differentiated drug pipeline addressing large neuropsychiatric indications.
